Quantcast

Latest Naproxcinod Stories

2011-09-28 09:08:55

An updated study published in this week's PLoS Medicine gives some new information on the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) and suggests that among these commonly used drugs, naproxen and low dose ibuprofen are least likely to increase cardiovascular risk whereas diclofenac, even in doses available without prescription, elevates risk. Using only observational studies (30 case-control studies and 21 cohort studies) because randomised controlled trials...

2010-03-03 06:00:00

ROCHESTER, N.Y. and SOPHIA ANTIPOLIS, France, March 3 /PRNewswire/ -- NicOx S.A. (NYSE Euronext Paris: COX) and Bausch + Lomb, a leading eye health company, today announced the companies have entered into a licensing agreement which grants Bausch + Lomb exclusive worldwide rights to develop and commercialize NCX 116 (previously PF-03187207), a nitric oxide-donating prostaglandin F2-alpha analog. Eye disease affects millions of people worldwide and can lead to impaired vision or total...

2009-07-08 06:58:00

LA JOLLA, Calif., July 8 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical company focused on developing non-invasive, topically administered products, today announced they have successfully completed the enrollment of patients in their pivotal Phase 3 clinical study for Ketotransdel(R), a topical cream based non-steroidal anti-inflammatory drug ("NSAID") for acute pain. Based on industry estimates, the market for NSAIDs and Cox-2...

2009-03-18 13:55:00

MORRISTOWN, N.J., March 18 /PRNewswire/ -- Concerns still persist within the general clinical community regarding the cardiovascular and gastrointestinal risk that is associated with the use of analgesics such as the nonsteroidal anti-inflammatory drugs (NSAIDs). In particular, the use of COX-2 selective inhibitor NSAIDs continues to raise the concern of cardio-renal complications not only in the decision making process of physicians but also in the perception of many patients who still...

2009-02-26 06:00:00

SOPHIA ANTIPOLIS, France, February 26 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced its financial results for full year 2008 and provided an overview of the development and pre-commercialization activities for naproxcinod, its lead investigational drug for the treatment of the signs and symptoms of osteoarthritis (OA). Michele Garufi, Chief Executive Officer of NicOx, commented: "We believe NicOx has entered 2009 in its strongest strategic position...

2008-12-23 06:00:00

SOPHIA ANTIPOLIS, France, December 23 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced the results of a phase 2a study for TPI 1020, conducted in 62 patients with Chronic Obstructive Pulmonary Disease (COPD) by its partner Topigen Pharmaceuticals Inc. TPI 1020 showed good overall safety and tolerability, although its activity profile was not significantly different from budesonide, a conventional corticosteroid commonly used in respiratory disorders. TPI...

2008-12-19 06:00:00

SOPHIA ANTIPOLIS, France, December 19 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced positive results from the 112 clinical pharmacology study in 299 patients with osteoarthritis (OA) and hypertension, which was designed to characterize the 24-hour blood pressure profile of naproxcinod in comparison to the two most widely used non-steroidal anti-inflammatory drugs (NSAIDs). At week 13, naproxcinod 750 mg bid showed a reduction in systolic blood pressure (SBP)...

2008-12-17 06:00:00

SOPHIA ANTIPOLIS, France, December 17 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced positive results of a pre-specified pooled analysis of 2,734 patients with osteoarthritis (OA) from the 301, 302 and 303 pivotal phase 3 studies for naproxcinod. Both doses of naproxcinod showed a significant reduction in systolic and diastolic blood pressure (SBP and DBP) compared to naproxen 500 mg bid over the whole 13 week period (p<0.001 for naproxcinod 750 mg bid...

2008-12-02 06:30:00

SOPHIA ANTIPOLIS, France, December 2 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced it has signed an agreement with DSM for the commercial manufacture and supply of naproxcinod drug substance (or API, active pharmaceutical ingredient). Naproxcinod is NicOx' lead investigational product and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which recently achieved positive results in the...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related